Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320957 | 1.00 | CFTR (0.43) | CFTRTRPV1CYP3A4CYP2D6KDM1A | |
| SCHEMBL3322619 | 0.87 | TRPV1 (0.41) | CFTRTRPV1CYP3A4KDM1A | |
| SCHEMBL3322624 | 0.87 | TRPV1 (0.41) | CFTRTRPV1CYP3A4KDM1A | |
| SCHEMBL6024931 | 0.87 | TRPV1 (0.41) | CFTRTRPV1CYP3A4KDM1A | |
| Cadaverine Tartrate SCHEMBL3319578 | 0.87 | CFTR (0.43) | CFTRTRPV1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL7826326 | 0.86 | TRPV1 (0.40) | CFTRTRPV1CYP3A4KDM1A | |
| SCHEMBL25660453 | 0.82 | HTR2C (0.36) | CFTRTRPV1CYP3A4CYP2D6HTR2A | |
| SCHEMBL10585393 | 0.81 | CNR1 (0.35) | CFTRTRPV1CYP3A4 | |
| SCHEMBL15086547 | 0.81 | TRPV1 (0.41) | CFTRTRPV1KDM1A | |
| SCHEMBL3574214 | 0.81 | TRPV1 (0.41) | CFTRTRPV1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107405337-B | Substituted chromans and methods of use | 艾伯维公司 | 2021-02-09 | — | — | CN | disclosed |
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| CN-107405337-A | Substituted chroman and application method | 艾伯维公司 | 2017-11-28 | — | — | CN | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2013-12-26 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | CFTR 257/4885TRPV1 1/4885CYP3A4 1282/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | CFTR 177/4885TRPV1 1/4885CYP3A4 3920/4885 |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CFTR 1/4885TRPV1 1470/4885CYP3A4 227/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | CFTR 247/4885TRPV1 1/4885CYP3A4 1264/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | CFTR 131/4885TRPV1 1/4885CYP3A4 3516/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CFTR 1/4885TRPV1 1470/4885CYP3A4 227/4885 |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | TRPV1, NPY1R, OPRL1 | CFTR 206/4885TRPV1 1/4885CYP3A4 2595/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | CFTR 300/4885TRPV1 4781/4885CYP3A4 276/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | CFTR 1/4885TRPV1 1470/4885CYP3A4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.